ANXA1 and oral lichen planus: Thus, from a therapeutic perspective, the availability of Annexin A1-mimetics (e.g., Ac2-26) and Annexin A1 receptor agonists (e.g., Compound 17b and Compound 43) should facilitate the investigation of their efficacy (e.g., via topical application to oral mucosa) in OC and OLP [5].